BioCardia, Inc. (NASDAQ:BCDA) Short Interest Update

BioCardia, Inc. (NASDAQ:BCDA) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 77,100 shares, an increase of 267.1% from the May 31st total of 21,000 shares. Based on an average trading volume of 128,700 shares, the short-interest ratio is presently 0.6 days. Approximately 6.0% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of BioCardia in a research report on Wednesday, May 29th.

BioCardia Stock Performance

Shares of NASDAQ:BCDA traded up $0.11 during trading on Thursday, reaching $3.01. The stock had a trading volume of 19,920 shares, compared to its average volume of 81,045. The business has a fifty day moving average price of $4.86 and a 200-day moving average price of $6.50. BioCardia has a fifty-two week low of $2.62 and a fifty-two week high of $43.17.

BioCardia (NASDAQ:BCDA) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($1.35) earnings per share for the quarter. BioCardia had a negative net margin of 2,208.76% and a negative return on equity of 3,638.68%. The firm had revenue of $0.06 million during the quarter. During the same period in the previous year, the company posted ($2.55) earnings per share. On average, equities analysts expect that BioCardia will post -6.3 EPS for the current year.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its leading product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.